Endo International (NASDAQ:ENDP) (TSE:ENL)‘s stock had its “hold” rating reissued by Oppenheimer in a research note issued on Tuesday.
Other analysts have also recently issued research reports about the company. Mizuho reiterated a “buy” rating on shares of Endo International in a research report on Friday, November 10th. Vetr cut Endo International from a “strong-buy” rating to a “buy” rating and set a $8.92 target price on the stock. in a research report on Monday, December 18th. B. Riley started coverage on Endo International in a research report on Wednesday, February 14th. They set a “buy” rating and a $10.00 target price on the stock. Barclays cut their target price on Endo International from $15.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Friday, February 23rd. Finally, ValuEngine cut Endo International from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Three research analysts have rated the stock with a sell rating, sixteen have given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Endo International presently has a consensus rating of “Hold” and an average price target of $10.32.
Shares of Endo International (ENDP) opened at $6.30 on Tuesday. The company has a current ratio of 1.08, a quick ratio of 0.86 and a debt-to-equity ratio of 10.78. Endo International has a 52-week low of $5.77 and a 52-week high of $14.45. The company has a market capitalization of $1,520.00, a PE ratio of -1.14, a PEG ratio of 2.39 and a beta of 0.29.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. River & Mercantile Asset Management LLP increased its position in Endo International by 32.7% during the 4th quarter. River & Mercantile Asset Management LLP now owns 475,650 shares of the company’s stock worth $3,679,000 after purchasing an additional 117,110 shares during the period. Van ECK Associates Corp increased its position in Endo International by 67.1% during the 3rd quarter. Van ECK Associates Corp now owns 340,991 shares of the company’s stock worth $2,921,000 after purchasing an additional 136,873 shares during the period. Alps Advisors Inc. increased its position in Endo International by 22.9% during the 4th quarter. Alps Advisors Inc. now owns 307,839 shares of the company’s stock worth $2,386,000 after purchasing an additional 57,328 shares during the period. UBS Asset Management Americas Inc. increased its position in Endo International by 4.4% during the 4th quarter. UBS Asset Management Americas Inc. now owns 221,992 shares of the company’s stock worth $1,720,000 after purchasing an additional 9,438 shares during the period. Finally, Quantitative Investment Management LLC acquired a new position in Endo International during the 4th quarter worth approximately $1,569,000. Institutional investors own 92.54% of the company’s stock.
Endo International Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.